View Older Stories View More Recent Stories

Sep 13, 2017 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 11, 2017 08:00AM Horizon Pharma plc Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer
Sep 5, 2017 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 24, 2017 08:00AM Horizon Pharma plc to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
Aug 7, 2017 07:00AM Horizon Pharma plc Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance
Aug 3, 2017 07:00AM Horizon Pharma plc Appoints Pascale Witz and James Shannon, M.D. to Board of Directors
Jul 25, 2017 08:00AM Horizon Pharma plc Launches CGD Connections™ to Deliver Support and Resources Created by and for the Chronic Granulomatous Disease (CGD) Community
Jul 14, 2017 08:08AM UPDATE: Horizon Pharma (HZNP) Presents Study Results for PROCYSBI (Cysteamine Bitartrate) Delayed-Release Capsules
Jul 14, 2017 08:00AM Horizon Pharma plc Announces Four Poster Presentations on PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules at Cystinosis Research Network 2017 Family Conference
Jul 10, 2017 10:50AM Horizon Pharma plc to Host Second-Quarter 2017 Conference Call and Webcast on Aug. 7, 2017
Jun 27, 2017 07:04AM UPDATE: Horizon Pharma (HZNP) Says District Court Upheld VIMOVO Patents
Jun 27, 2017 07:00AM Horizon Pharma plc Announces District Court Decision to Uphold VIMOVO® (naproxen/esomeprazole magnesium) Patents
Jun 23, 2017 11:18AM National Health Partners (HPR) Finalizes Sale of European Marketing Rights for PROCYSBI & QUINSAIR in EMEA Regions to Chiesi Farmaceutici S.p.A. for $72.2M Plus Milestone Payments
Jun 23, 2017 11:00AM Horizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe, Middle East
Jun 20, 2017 03:00PM Horizon Pharma plc Partners with Global Genes® to Unite the Rare Disease Community at the Biotechnology Innovation Organization (BIO) International Convention
Jun 19, 2017 08:05AM Horizon Pharma (HZNP) Announces Health Canada Approval of PROCYSBI for Treatment of Nephropathic Cystinosis
Jun 19, 2017 08:00AM Horizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic Cystinosis
Jun 14, 2017 09:08AM Horizon Pharma (HZNP) Presents Data Analyses Showing Clinical Benefit of KRYSTEXXA in Patients with Uncontrolled Gout
Jun 14, 2017 09:05AM Horizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled Gout
Jun 14, 2017 09:00AM Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993
May 26, 2017 07:00AM Horizon Pharma plc to Participate in Upcoming Conferences
May 25, 2017 01:00PM Horizon Pharma plc Named One of the Best Workplaces in Chicago by Fortune
May 23, 2017 04:06PM Horizon Pharma (HZNP) to Sell European Marketing Rights to PROCYSBI and EMEA Rights to QUINSAIR
May 23, 2017 04:05PM Horizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Mi
May 15, 2017 07:09AM Horizon Pharma (HZNP) Announces District Court Decision to Uphold PENNSAID 2% w/w Patent
May 15, 2017 07:00AM Horizon Pharma plc Announces District Court Decision to Uphold PENNSAID® (diclofenac sodium topical solution) 2% w/w Patent
May 11, 2017 09:00AM Horizon Pharma plc Announces Michelle Parsons as a 2017 Healthcare Businesswomen's Association Luminary
May 8, 2017 07:00AM Horizon Pharma plc Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance
May 8, 2017 06:57AM Horizon Pharma (HZNP) to Acquire River Vision Development Corp. and Teprotumumab (RV001) for $145M Upfront Plus Milestones
May 8, 2017 06:55AM Horizon Pharma plc Announces Agreement to Acquire River Vision Development Corp. and Teprotumumab (RV001), a Biologic in Late-Stage Development for Rare Eye Disease
May 1, 2017 07:11AM Horizon Pharma (HZNP) Announces FDA Approval to Expand Age Range for RAVICTI Oral Liquid to Treat UCDs
May 1, 2017 07:00AM Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to People with Urea Cycle Disorders Two Months of Age and Older
Apr 13, 2017 07:00AM Horizon Pharma plc to Host First-Quarter 2017 Conference Call and Webcast on May 8, 2017
Apr 12, 2017 11:00AM Horizon Pharma plc Named One of the Best Workplaces in Health Care by Great Place to Work® and Fortune Magazine
Apr 7, 2017 08:00AM Horizon Pharma plc Named to the Crain’s Chicago Business 2017 “Best Places To Work” List
Mar 30, 2017 07:11AM Horizon Pharma (HZNP) Granted Additional USPTO Notice of Allowance With Claims Covering VIMOVO Delayed Release Tablets
Mar 30, 2017 07:00AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO® (naproxen/esomeprazole) Delayed Release Tablets
Mar 22, 2017 09:06AM Horizon Pharma (HZNP) to Present Data on RAVICTI Oral Liquid for Urea Cycle Disorder Patients at ACMG
Mar 22, 2017 09:00AM Horizon Pharma plc to Present Data on RAVICTI® (glycerol phenylbutyrate) Oral Liquid for Urea Cycle Disorder Patients Aged Two Months to Two Years
Mar 16, 2017 09:30AM Horizon Pharma plc Announces "UCD in Common" for the Urea Cycle Disorder (UCD) Community
Mar 2, 2017 08:00AM Horizon Pharma plc Announces Urea Cycle Disorders Medical Foods and Supplements Financial Assistance Program
Feb 28, 2017 08:00AM Horizon Pharma plc Launches RAREis™ Campaign Elevating Faces of the Rare Disease Community
Feb 27, 2017 07:00AM Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Full-Year 2017 Net Sales and Adjusted EBITDA Guidance
Feb 14, 2017 08:00AM Horizon Pharma plc to Participate in Cowen and Company 37th Annual Health Care Conference
Jan 27, 2017 08:00AM Horizon Pharma plc to Host Fourth-Quarter 2016 Conference Call and Webcast on February 27, 2017
Jan 17, 2017 12:00PM Global Genes® and Horizon Pharma plc Partner to Offer Nephropathic Cystinosis Scholarships
Dec 22, 2016 04:08PM Horizon Pharma (HZNP) Announces Issuance of Additional Notice of Allowance Covering RAVICTI
Dec 22, 2016 04:05PM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
Dec 22, 2016 07:30AM Horizon Pharma plc to Present at the 35th Annual J.P. Morgan Healthcare Conference
Dec 22, 2016 07:02AM Horizon Pharma (HZNP) QUINSAIR Now Available in Canada to Treat Lung Infections in Adults with CF
View More Recent Stories View Older Stories